Modified, autologous T-cell immunotherapies have been transformative in the treatment of hematologic malignancies with several approvals of chimeric antigen receptor T-cell therapies to treat lymphoma ...

Hematologic malignancy patients face high COVID-19 risk, with 23.5% experiencing severe illness despite vaccination. Mortality rate was 22.4%, influenced by age, active disease, and ICU admission.

Fewer than 1% of all causes of ascites are attributed to conditions other than liver cirrhosis, cardiac disease or malignancy. In this case, the patient presented with massive splenomegaly and later ...

The data from patients without hematologic cancer were pooled from both studies. Eli-cel denotes elivaldogene autotemcel, G-CSF granulocyte colony-stimulating factor, ND not determined, and VCN vector ...

The study cohort comprised 186 patients with a mean age of 57.1 ± 13.4 years, 101 of whom were male and 18 of whom had hematologic malignancies. The median survival time was 201 days in the ...

Physical condition is the primary reason patients with blood cancers don’t receive treatment, followed by patient/family choice. In a new study, female patients were more likely than males to decline ...